Sugi Predict

Sugi Predict / Compounds / SCHEMBL319861

SCHEMBL319861

SCHEMBL319861

COc1ccc(CN(c2nncs2)S(=O)(=O)c2cc(Cl)c(Sc3cccc(C(F)(F)F)c3)cc2F)c(OC)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 13/20 0.35
▸ SLC6A2 P23975 2/20 0.35
▸ SLC6A4 P31645 2/20 0.35
▸ CYP2C9 P11712 2/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN2A Q99250 1/20 0.34
▸ SCN8A Q9UQD0 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ S1PR2 O95136 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16223620 0.93 SMN1; SMN2 (0.33) SCN9ASCN1ASCN8ASMN1; SMN2MEN1
SCHEMBL16223640 0.92 SCN9A (0.35) SCN9ASLC6A2SLC6A4CYP2C9SCN1A
SCHEMBL16223540 0.91 THRB (0.33) SCN9ASMN1; SMN2MEN1POLBKMT2A
SCHEMBL319968 0.89 NPC1 (0.35) SCN9ASLC6A4SCN1ASCN8ASMN1; SMN2
SCHEMBL16223538 0.88 NPC1 (0.33) SCN9ASCN1ASCN8ASMN1; SMN2LMNA
SCHEMBL16223588 0.87 KDM4E (0.36) SCN9ACYP2C9SCN1ASCN2ASCN8A
SCHEMBL16223775 0.86 MEN1 (0.34) SCN9ASCN1ASCN8ASMN1; SMN2MEN1
SCHEMBL16223569 0.86 NPC1 (0.34) SCN9ASCN1ASCN8ASMN1; SMN2MEN1
SCHEMBL10129756 0.85 SCN9A (0.47) SCN9ACYP2C9SCN1ASCN2ASCN8A
SCHEMBL10129962 0.83 SCN9A (0.40) SCN9ACYP2C9SCN1ASCN2ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 — — US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 — — US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 — — US disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 — — EP disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 — — EP disclosed
EP-2590957-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 — — EP disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109696-A1 Chemical Compounds SCN1A, SCN7A, SCN1B SCN9A 10/4885SLC6A2 446/4885SLC6A4 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.